Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Raises $2.4M in Issue of Shares to Institutional Investor

Premium

Proteome Sciences this week said it has raised roughly £1.57 million ($2.44 million) in an issue of shares to an unnamed institutional investor.

The company said it received a direct approach from the investor to subscribe for 3.75 million new ordinary shares at a price of 41.5 pence per share. The funds will be used as additional working capital to develop the business, it said.

The company has applied to the London Stock Exchange for the admission of the new shares and said that it expects that the admission will occur on August 12.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.